LivaNova (LIVN) EBITDA Margin (2014 - 2026)

LivaNova (LIVN) posted EBITDA Margin of 11.45% for Q1 2026, down 2.96% sequentially from 11.8% in Q4 2025, and down 390.0% YoY from 3.95% in Q1 2025.

LivaNova (LIVN) EBITDA Margin (2014 - 2026) Analysis & Trends

LivaNova has reported EBITDA Margin for 13 years, with the latest figure at 11.45% in Q1 2026.

Quarterly EBITDA Margin fell 390.0% year-over-year to 11.45% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.41% (up 75.0% YoY) and the FY2025 annual result came in at 14.36%, up 407.0% from the prior year.
EBITDA Margin declined to 11.45% in Q1 2026 per LIVN's latest filing, from 11.8% in the prior quarter.
Over five years, EBITDA Margin peaked at 15.37% in Q2 2025 and troughed at 52.24% in Q3 2022.
A 5-year average of 3.37% and a median of 11.2% in 2024 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2022 and 2023: EBITDA Margin sank 5873 bps in 2022, then surged 5380 bps in 2023.
Over 5 years, EBITDA Margin stood at 5.08% in 2022, then sank by 659 bps to 28.37% in 2023, then soared by 141 bps to 11.5% in 2024, then advanced by 3 bps to 11.8% in 2025, then slipped by 3 bps to 11.45% in 2026.
According to Business Quant data, EBITDA Margin over the past three periods registered 11.45%, 11.8%, and 15.1% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Abbott Laboratories	199.63 Bn	194.02 Bn	7.27 Bn	13.44%
2	Stryker	127.42 Bn	123.95 Bn	4.50 Bn	25.18%
3	Medtronic	118.97 Bn	109.75 Bn	6.41 Bn	19.10%
4	Boston Scientific	73.39 Bn	72.85 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	51.97 Bn	47.72 Bn	1.35 Bn	29.48%
6	Dexcom	34.32 Bn	32.37 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	33.76 Bn	31.65 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.35 Bn	23.03 Bn	4.55 Bn	10.30%
9	Steris	23.04 Bn	22.56 Bn	684.20 Mn	19.15%
10	LivaNova	4.31 Bn	3.79 Bn	273.67 Mn	12.67%

Download Data